Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics, Inc.    SRPT

SAREPTA THERAPEUTICS, INC.

(SRPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
132.71(c) 134.42(c) 131.18(c) 134.49(c) 135.11(c) Last
577 053 591 765 455 304 415 639 484 982 Volume
-5.04% +1.29% -2.41% +2.52% +0.46% Change
More quotes
Financials (USD)
Sales 2020 539 M - -
Net income 2020 -527 M - -
Net cash position 2020 777 M - -
P/E ratio 2020 -19,9x
Yield 2020 -
Sales 2021 742 M - -
Net income 2021 -457 M - -
Net cash position 2021 752 M - -
P/E ratio 2021 -24,6x
Yield 2021 -
Capitalization 10 662 M 10 662 M -
EV / Sales 2020 18,3x
EV / Sales 2021 13,4x
Nbr of Employees 743
Free-Float 95,2%
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug... 
More about the company
Notations Surperformance© of Sarepta Therapeutics, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about SAREPTA THERAPEUTICS, INC.
11/23SAREPTA THERAPEUTICS : Named One of The Boston Globe's Top Places to Work 2020
AQ
11/20SAREPTA THERAPEUTICS : Named One of The Boston Globe's Top Places to Work 2020
AQ
11/20Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020
GL
11/09BIOGEN : plunges 30% after FDA panel votes against Alzheimer's drug
RE
11/05SAREPTA THERAPEUTICS : 3Q Earnings Snapshot
AQ
11/05SAREPTA THERAPEUTICS : 3Q 2020 Forward Looking Statement
PU
11/05SAREPTA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditi..
AQ
11/05SAREPTA THERAPEUTICS : Announces Third Quarter 2020 Financial Results and Recent..
AQ
11/05Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recen..
GL
11/05SAREPTA THERAPEUTICS : to Commence Dosing of the Next Study with Commercial Proc..
AQ
11/05Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Pro..
GL
11/02SAREPTA THERAPEUTICS : to Present at the 29th Annual Credit Suisse Virtual Healt..
AQ
11/02Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Heal..
GL
10/30SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
10/30Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
More news
News in other languages on SAREPTA THERAPEUTICS, INC.
09/28ROCHE : Sarepta revendique des progrès contre la myopathie de Duchenne
07/24Bourse Zurich: la prudence de retour pour la dernière séance de la semaine
07/24ROCHE : procédure accélérée pour une molécule de Sarepta
07/24ROCHE : statut de revue prioritaire pour un médicament contre la DMD
2019EN DIRECT DES MARCHES : Sanofi, Renault, Virbac, Marie Brizard, Recylex, Créd..
More news
Analyst Recommendations on SAREPTA THERAPEUTICS, INC.
More recommendations
Chart SAREPTA THERAPEUTICS, INC.
Duration : Period :
Sarepta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 188,38 $
Last Close Price 135,11 $
Spread / Highest target 60,6%
Spread / Average Target 39,4%
Spread / Lowest Target 3,62%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Wilsey Chairman
Joseph Bratica VP, Controller, CFO & Chief Accounting Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Hans Lennart Rudolf Wigzell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS, INC.4.70%10 662
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.59.64%38 761
BIONTECH SE200.68%24 529